



EDCTP

European & Developing Countries
Clinical Trials Partnership

Frequently asked questions (FAQs)

Vaccines for poverty-related diseases

Disclaimer: The FAQs are for information only and do not constitute a legally binding document. The legal basis for information in the FAQs can be found in the Horizon 2020 Rules for Participation and the EDCTP Annual Work Plans.



For more information, please go to the EDCTP website: www.edctp.org

Purpose of the FAQs

These FAQs provide guidance for applicants to the EDCTP2 Call for Proposals “Vaccines for poverty-related diseases” to supplement the information provided in the Call text and Call documents. The FAQs will be updated regularly in response to the questions received from applicants to the call. Please also refer to the [EDCTP2 FAQs](#).

Application

Q: Is this a single or two-stage application procedure?

A: The Vaccines for poverty-related diseases Call is a two-stage application. Only proposals successful in Stage 1 will be selected to proceed to Stage 2.

Q: What are the application deadlines for this Call?

A: Please refer to the “[Our Calls](#)” page of the EDCTP website for all the information on specific deadlines. For this call, the deadlines are as follows:

Stage 1 Open date	7 July 2016, 17:00 (GMT+1)
Stage 1 Close date	13 October 2016, 17:00 (GMT+1)
Indicative Stage 2 Open date	22 December 2017, 17:00 (GMT+1)
Indicative Stage 2 Close date	16 March 2017, 17:00 (GMT+1)

Q: What disease areas are within the scope of this Call for Proposals?

A: Proposals addressing any disease area within the EDCTP remit (a list can be found on our [website](#), or see Note 1 in the Call text) are eligible, with the exception of Ebola Virus Disease vaccine development since it has already been extensively funded by other parts of the Horizon 2020 programme.

Q: Does my proposal have to include a clinical trial?

A: Yes: Applications must include at least one clinical trial (Phase I to IV) which will be carried out in sub-Saharan Africa to test the safety, immunogenicity and/or efficacy of the vaccine(s). For Stage 1, full details of the clinical trial are not required however applicants must ensure that relevant aspects of the clinical trial(s) proposed are described in sufficient detail. Full details of the clinical trial will be requested in Stage 2.

Q: Can I add components of pre-clinical /basic/implementation research to the proposal?

A: Projects may include detailed analyses of host responses to advance the understanding of mechanisms of reactogenicity (safety), immunogenicity and/or efficacy. Other relevant sub-studies may be included in the proposal; however, these should be justified in the context of the main trial(s).

Q: The Call Text states that support from other funders is encouraged- where should I address this in the application form?

A: For Stage 1 a brief description of co-funding commitment from other sources should be described in the Excellence section of the proposal if available. Full details of any commitments are only

requested during Stage 2 where support letters may be uploaded as attachments to the main proposal.

Q: The Call Text states that projects should incorporate activities to enhance and or develop the capacity of trial sites in sub-Saharan Africa - is infrastructure also included in this?

A: Funding requested to develop or enhance the capacity of trial sites must be justified in the context of the proposed trials to be conducted. Large infrastructure requests such as new buildings and/or extensive renovations of buildings are not normally supported.

Q: I would like to include figures or tables to support my application- where can I do this?

A: For Stage 1 proposals, applicants may upload a single page attachment in the Excellence section of the proposal. For Stage 2 applications, a clinical trial template should be completed for each clinical trial proposed. In addition, the clinical trial protocols (draft or final) may be uploaded.